LLY

1,110.69

+4.11%↑

JNJ

226.13

+1.11%↑

ABBV

220.1

+1.64%↑

UNH

396.97

+3.06%↑

MRK

119.01

+2.39%↑

LLY

1,110.69

+4.11%↑

JNJ

226.13

+1.11%↑

ABBV

220.1

+1.64%↑

UNH

396.97

+3.06%↑

MRK

119.01

+2.39%↑

LLY

1,110.69

+4.11%↑

JNJ

226.13

+1.11%↑

ABBV

220.1

+1.64%↑

UNH

396.97

+3.06%↑

MRK

119.01

+2.39%↑

LLY

1,110.69

+4.11%↑

JNJ

226.13

+1.11%↑

ABBV

220.1

+1.64%↑

UNH

396.97

+3.06%↑

MRK

119.01

+2.39%↑

LLY

1,110.69

+4.11%↑

JNJ

226.13

+1.11%↑

ABBV

220.1

+1.64%↑

UNH

396.97

+3.06%↑

MRK

119.01

+2.39%↑

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

28.7 1.85

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.24

Massimo

28.78

Metriche Chiave
By Trading Economics
Entrata	669M 356M
Vendite	521K 2.5M
Margine di Profitto	14,116.825
Dipendenti	721
EBITDA	-65M -354M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.91% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	32M 20B
Apertura precedente	26.85
Chiusura precedente	28.7

Notizie sul Sentiment di mercato

By Acuity

24%

76%

56 / 344 Classifica in Healthcare

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 giu 2026, 23:22 UTC

Utili

I principali Market Mover

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 giu 2026, 23:09 UTC

Azioni calde

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 giu 2026, 20:51 UTC

Utili

Costco Reports 15% Sales Growth in May

3 giu 2026, 20:43 UTC

Utili

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 giu 2026, 23:15 UTC

Discorsi di Mercato

Utili

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 giu 2026, 22:08 UTC

Azioni calde

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 giu 2026, 21:54 UTC

Discorsi di Mercato

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 giu 2026, 21:18 UTC

Utili

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 giu 2026, 21:15 UTC

Utili

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 giu 2026, 21:13 UTC

Utili

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 giu 2026, 21:13 UTC

Utili

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 giu 2026, 21:12 UTC

Utili

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 giu 2026, 21:09 UTC

Utili

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 giu 2026, 21:03 UTC

Utili

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 giu 2026, 20:43 UTC

Utili

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 giu 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 giu 2026, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 giu 2026, 20:35 UTC

Utili

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 giu 2026, 20:17 UTC

Utili

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 giu 2026, 20:17 UTC

Utili

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Adj EPS $2.44 >AVGO

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q EPS $1.91 >AVGO

3 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Rev $22.19B >AVGO

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

33.91% in crescita

Previsioni per 12 mesi

Media 37.83 USD 33.91%

Alto 42 USD

Basso 31.5 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

56 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.